Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
CAMBRIDGE, Mass., Oct. 03, 2018 (GLOBE NEWSWIRE) --
- Data to be presented from the BIIB092 program for progressive supranuclear palsy and BIIB054 program for Parkinson’s disease highlight Biogen’s commitment to furthering movement disorders research
- Biogen’s Phase 2 PASSPORT study of BIIB092 for PSP has completed enrollment and BIIB092 has received fast track designation by the U.S. Food and Drug Administration for PSP
Biogen Inc. (Nasdaq:BIIB) announced it will present data from its movement disorders portfolio at the upcoming International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Hong Kong (Oct. 5-9, 2018). Data being presented are from Biogen’s research programs evaluating potential treatments for progressive supranuclear palsy (PSP) and Parkinson’s disease (PD) as part of its larger neurology pipeline.
“The data being presented at MDS are a testament to Biogen’s commitment to its goal of delivering innovative therapies for people living with complex, neurodegenerative conditions like PSP and PD,” said Kate Dawson, M.D., vice president of late-stage clinical development at Biogen. “PSP and PD both have significant unmet need, especially for disease modifying therapies, so we look forward to advancing the clinical development programs to help better understand these challenging conditions.”
Biogen PSP presentations will focus on safety data from the Phase 1 long-term extension study and baseline demographics from the Phase 2 PASSPORT study. The company’s BIIB092 program has recently met milestones, including recruitment completion for the Phase 2 PASSPORT study and fast track designation by the U.S. Food and Drug Administration for PSP. PSP is a rare neurodegenerative disease, considered to be a primary tauopathy, characterized by rapidly progressing physical impairments, such as difficulty speaking, swallowing and walking, as well as cognitive/behavioral impairments, such as apathy and dementia.
PD presentations will feature an overview of the design of the BIIB054 SPARK Phase 2 study, which is the most advanced program in Biogen’s PD pipeline. PD is the second most common neurodegenerative disease after Alzheimer’s disease. Motor symptoms of PD include bradykinesia, muscular rigidity, rest tremor and postural and gait impairment.1
Biogen’s presentations highlight:
- Safety analysis of an open-label extension study of BIIB092 in participants with PSP – POSTER, Abstract #43 – Saturday, Oct. 6, 13:45 – 15:15 HKT
- PASSPORT, an ongoing Phase 2 study in patients with PSP– baseline characteristics – POSTER, Abstract #8 – Saturday, Oct. 6, 13:45 – 15:15 HKT
- Prevalence and characteristics of patients with progressive supranuclear palsy (PSP) in US health insurance claims data –POSTER, Abstract #795 – Sunday, Oct. 7, 13:45 – 15:15 HKT
- Burden of progressive supranuclear palsy: a systematic literature review – POSTER, Abstract #921 – Sunday, Oct. 7,13:45 – 15:15 HKT
- Effect of PD medication on disease progression as measured by rate of change in MDS_UPDRS and DaT SBR in PPMI study – POSTER, Abstract #11– Saturday, Oct. 6, 13:45 – 15:15 HKT
- Design and status of the BIIB054 SPARK trial – POSTER, Abstract #39 – Saturday, Oct. 6, 13:45 – 15:15 HKT
- Quantitative assessment of appendicular bradykinesia in PD using wearable sensors – POSTER, Abstract #1131 – Sunday, Oct. 7, 13:45 – 15:15 HKT
- Effects of LDOPA on quantitative gait parameters measured with wearable sensors – POSTER, Abstract #1137 – Sunday, Oct. 7, 13:45 – 15:15 HKT
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.
We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about the Phase 1 long-term extension study and Phase 2 study of BIIB092 and the Phase 2 study of BIIB054; the potential clinical effects of BIIB092 and BIIB054; the potential benefits, safety and efficacy of BIIB092 and BIIB054; the identification and treatment of PSP; the potential of Biogen’s commercial business and pipeline programs, including BIIB092 and BIIB054; and risks and uncertainties associated with drug development and commercialization. These statements may be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including without limitation uncertainty of success in the development and potential commercialization of BIIB092 and/or BIIB054; the risk that we may not fully enroll our clinical trials or enrollment will take longer than expected; unexpected concerns may arise from additional data, analysis or results obtained during our clinical trials; regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of our drug candidates, including BIIB092 and/or BIIB054; the occurrence of adverse safety events; unexpected costs or delays; we may encounter other unexpected hurdles; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; and product liability claims. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our most recent annual or quarterly report and in other reports we have filed with the Securities and Exchange Commission. These statements are based on our current beliefs and expectations and speak only as of the date of this press release. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.
1 Kalia LV, Lang AE. Parkinson’s disease, Lancet. 2015 Aug 29;386(9996):896-912
+1 617 679 4945
+1 781 464 2442
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Must Read Whitepaper, ‘Making Money With Network Slicing’, Hits The Shelves23.10.2018 10:00 | Pressemelding
Network Slicing Leader Cloudstreet Showcases the Vast Opportunities of this Promising New Mobile Business Model Espoo, Finland & Berlin, Germany, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Cloudstreet, ‘The Network Slicing Company’, is pleased to announce the publication of its most recent industry whitepaper, “Making Money with Network Slicing”. A business-forward take on the practice, the paper puts slicing at the very center of the mobile industry’s transition now underway. With a focus on practical, market-ready models, the authors unravel the misconceptions about Network Slicing, exploring its potential to disrupt the cultural and business logjams that have hampered growth. Less about technology than a new way of doing business, Network Slicing has quickly risen from a mere buzzword to a budget line item, as mobile operators retool for the opportunities to come “Inherently disruptive, it will create new business ecosystems to support unique and evolving demands that touch quite literally e
Skybox Security Receives Common Criteria Certification23.10.2018 09:00 | Pressemelding
Receiving the internationally recognized certification will help organizations and particularly federal agencies assess the security and assurance of Skybox solutions SAN JOSE, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Skybox® Security, a global leader in cybersecurity management, has received Common Criteria for Information Technology Security Evaluation (Common Criteria or CC) certification for Skybox Security Suite. Skybox is honored to receive the high-standard certification, demonstrating our commitment to top-tier products and delivering premium solutions to our customers. “The Common Criteria certification is an important milestone for the Skybox product,” said Skybox Security Vice President of R&D and CTO Ron Davidson. “It also enables us to provide cybersecurity solutions in the federal space, which not only requires the CC stamp of approval, but also has an acute need for the attack surface visibility and situational intelligence Skybox delivers.” The Skybox Security Suite en
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus23.10.2018 07:00 | Pressemelding
BRUSSELS, Belgium and CAMBRIDGE, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Today UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) announced top-line results from a Phase 2b study evaluating the safety and efficacy of dapirolizumab pegol (DZP), an anti-CD40L pegylated Fab, in adults with moderately-to-severely active systemic lupus erythematosus (SLE) despite receiving standard-of-care treatment such as corticosteroids, anti-malarials and non-biological immunosuppressants. The primary endpoint of the study to demonstrate a dose response at 24 weeks on the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) was not met (p=0.06). The study did demonstrate consistent and potentially meaningful improvements for the majority of clinical endpoints in patients treated with DZP compared with placebo. In addition, biomarker data demonstrated evidence of proof of biology. DZP was well tolerated and demonstrated an acceptable safety profile. Biogen and U
Constellation Brands Prices Offering of Senior Notes22.10.2018 23:52 | Pressemelding
VICTOR, N.Y., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ and STZ.B), a leading beverage alcohol company, announced today that it priced the public offering of $2.15 billion aggregate principal amount of Senior Notes, consisting of (i) $650.0 million of Senior Floating Rate Notes due 2021 (the “senior floating rate notes”); (ii) $500.0 million of 4.400% Senior Notes due 2025 (the “2025 notes”) for a public offering price of 99.812% of the principal amount of the 2025 notes; (iii) $500.0 million of 4.650% Senior Notes due 2028 (the “2028 notes”) for a public offering price of 99.720% of the principal amount of the 2028 notes; and (iv) $500.0 million of 5.250% Senior Notes due 2048 (the “2048 notes”) for a public offering price of 99.592% of the principal amount of the 2048 notes (collectively, the “notes”). The notes will be senior obligations that rank equally with all of Constellation’s other senior unsecured indebtedness, and will be guaranteed by the subs
Forterra Announces Third Quarter 2018 Earnings Schedule22.10.2018 22:30 | Pressemelding
IRVING, Texas, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra”) (Nasdaq: FRTA) plans to release third quarter 2018 financial results before the market opens on Tuesday, November 6, 2018. A conference call to review financial results will also be held on Tuesday, November 6, 2018 at 10:00 a.m. Eastern time (9:00 a.m. Central). Hosting the call will be Jeff Bradley, Chief Executive Officer, and Charlie Brown, Executive Vice President and Chief Financial Officer. CONFERENCE CALL AND WEBCAST DETAILS Webcast Information Event: Q3 2018 Forterra, Inc. Earnings Call Date: Tuesday, November 6, 2018 Time: 10:00 a.m. Eastern Time (9:00 a.m. Central) https://edge.media-server.com/m6/p/6dinjr8x Conference Call Information U.S.: 1-574-990-1396 Toll-Free: 1-844-498-0572 Participant Passcode: 2467118 Replay Information A replay of the conference call will be available within 24 hours after the call on the “Events & Presentations” page under the Investor section of the Company’s website at
Ondot Announces Investment from Citi Ventures to Power Enriched Transactions22.10.2018 17:00 | Pressemelding
The investment will fuel Ondot’s international growth and give cardholders accessing info via Ondot’s platform increased control over and visibility into each transaction Santa Clara, Ca, Oct. 22, 2018 (GLOBE NEWSWIRE) -- Ondot Systems, the global leader in mobile payments services, today announced that it has secured a strategic funding investment from Citi Ventures. Ondot works directly with financial institutions to give consumers increased control over and visibility into their personal payment transactions. With Ondot, consumers can manage functions such as fraud alerts, transaction limits and purchase location restrictions, all from the convenience of an app on their smartphone or desktop. This investment will further support Ondot’s efforts to grow its international presence and product offerings. Today’s digitally connected consumers are looking for more ways to access detailed information about their digital lives — including personal payment transactions. Ondot’s platform add
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom